MK 3475 - 669 – A Phase III Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

MK 3475-689 – A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NIS-HANNA – A National, Prospective, Non-Interventional Study (NIS) of Nivolumab in Patients with Squamous Cell Carcinom of the Head and Neck (SCCHN) progressing on or After Platinum-Based Therapy.